Borison 1989.

Methods	Randomisation: randomised, no further details. Allocation: procedure not described. Blinding: double, no further details. Duration: 6 weeks. Design: parallel. Location: n.i., Setting: n.i.,
Participants	Diagnosis: schizophrenia (DSM‐III). N = 10. Gender: n.i., Age: range 18‐60 years. History: duration stable ‐ n.i., duration ill ‐ n.i., nr. of prev. hospitalisations ‐ n.i., age at onset ‐ n.i., severity of illness ‐ min. 35 on BPRS, baseline antipsychotic dose ‐ n.i.,
Interventions	1. Haloperidol: flexible dose, allowed dose range 15 to 75 mg/t.i.d., mean dose n.i.. N = 8. 2. Thioridazine: flexible dose, allowed dose range 150 to 750 mg/t.i.d., mean dose n.i.. N = 8. Other medication: chloral hydrate.
Outcomes	Response to treatment: BPRS (no definition). Mental state: BPRS. Relapse. Leaving the study early. Adverse events : movement disorders (akathisia, dystonia, rigor, use of antiparkinson medication), other adverse effects (hypotension, sedation).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Procedure not described.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double, no further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double, no further details.
Incomplete outcome data (attrition bias) All outcomes	High risk	1 out of 8 participants from the thioridazine group (13%) left the study early due to inefficacy of treatment. 3 out of 8 participants from the haloperidol group (38%) left the study early to due improvement and administrative reasons. Drop‐outs were not included in the final analysis.
Selective reporting (reporting bias)	Low risk	No evidence for selective reporting.
Other bias	Low risk	No clear other bias.